Short answer
Zimmer Biomet (ZBH) filed an 8-K current report with the SEC on April 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results for quarter ended March 31, 2026.
Zimmer Biomet 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026
- Press release issued April 28, 2026
- Exhibit 99.1 contains financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q1 sales $2.087B, up 9.3% reported and 2.9% organic constant currency, indicating acquisition and currency effects drove much growth
- Adjusted diluted EPS $2.09, up 15.5%; GAAP EPS $1.22, up 34.1%
- S.E.T. sales rose 19.5% reported but only 1.6% organically, highlighting Paragon 28’s significant contribution
- Updated 2026 adjusted EPS guidance to $8.40–$8.55 from $8.30–$8.45
- $250.1M share repurchases and $245.9M free cash flow support shareholder returns despite cash falling to $424.2M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zimmer Biomet 8-K filings
Get the next ZBH 8-K as it lands
Follow ZBH for push alerts, or ask the research agent what this filing means.